← board
CEROW
distress 4/10 · elevated risk$0.01+233%today0% from 52w high
Lead: hematological malignancies
Revenue
pre-revenue
Liquidity
$1M
Runway
—
Shares 1y
+3642%
Price & events
+233.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+233.3%
1D
+233.3%
1W
—
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
+233.3%
All
Overview
- Market Cap
- $225.56K
- Enterprise Value
- $-495.16K
- Volume
- 25.00K
- 52 Week Range
- $0.00 – $0.01
- Total Shares
- 45.11M
- Float Shares
- 43.33M
- RVOL
- 1.82x
- Beta
- 0.16
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025trial initiationsecondaryPhase 1CER-1236 · Anticipates initiating clinical trials in 2025SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — hematological malignancies
Recent news
- 2026-06-22CERo Therapeutics Holdings Inc (CEROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-06-17CERo Therapeutics Holdings Inc (CEROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-06-17CERo Therapeutics Holdings Inc - TradingKey
- 2026-04-14CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial - Yahoo Finance
- 2026-02-17CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.